Pharma retail bucks the slowdown trend
Mumbai, June 14, 2012: The pharma retail market grew by a commendable 17% for the 12-month period ending May, according to the data by All India Organisation of Chemists and Druggists (AIOCD). Rising above the gloomy state prevailing in the economy, the rise came on the back of strong growth in segments like vitamin supplements and diabetes drugs.
The data from AIOCD also said that the companies that had a decent portfolio in segments like cardiac and diabetic have been able to play an important role in this growth-run. Within the chronic segment, anti-diabetic business registered a growth of 29% while the cardiac therapy grew by 21% in the last year.
Companies like Sun Pharma, Macleods, Mankind and Zydus Cadila are the few names that have registered high growth during the last year. For the record, in the highly-fragmented retail market valued at Rs. 65,000 crore ($11.73 billion) per annum, Abott stands at the pole position with a 5.42% market share followed by Cipla and Sun Pharma at 4.99% and 4.91% respectively.
As a result of Sun Pharma’s 21.6% growth, GlaxoSmithKline moved down to the fourth position with a market share of 4.75%. Other names like Zydus (including Biochem) and Ranbaxy accounted for 4.53% and 3.88% of the market respectively.